Vector Oncology is proud to recognize two physicians that have joined their scientific team, Dr. Ari VanderWalde and Dr. Daruka Mahadevan. The scientific passion and leadership of these men, along with the work of our supporting associates, make us truly unique as a company. Their research, clinical and pharmaceutical experience help us achieve our vision of enhancing the speed, quality and efficiency of precision oncology research while also contributing to the care, treatment experience and health outcomes of cancer patients worldwide.

Dr. Ari VanderWalde

Dr. Ari VanderWalde Senior Medical Director

Dr. Ari VanderWalde
Senior Medical Director

Ari VanderWalde, MD, MPH, Mbioeth, serves as Senior Medical Director at Vector Oncology. He received his medical degree in 2005 from the University of Pennsylvania School of Medicine in Philadelphia after graduating cum laude from Harvard University. He obtained a Master’s degree from both the University of Pennsylvania Center for Bioethics and Harvard School of Public Health. He completed internal medicine training UCLA (internship and residency) and a joint fellowship in Hematology/Oncology at City of Hope Comprehensive Cancer Center and Harbor-UCLA Medical Center. He is board-certified in Internal Medicine and Medical Oncology.

“As a medical oncologist, researcher and past leader in a large biopharmaceutical company, I am thrilled to be a part of Vector Oncology. Vector offers high-level scientific support, data and processes to advance both the practice and outcomes of oncology research.”

Dr. Daruka Mahadevan

Dr. Daruka Mahadevan Medical Scientist

Dr. Daruka Mahadevan
Medical Scientist

Daruka Mahadevan, MD, PhD, serves as Medical Scientist specializing in Phase I studies and works closely with our teams to provide informed opinion with regard to novel agents and optimal approaches to clinical development.

Dr. Mahadevan is the former Associate Professor of Medicine and Director of the Phase I, New Drug Development Program at the University of Arizona – Arizona Cancer Center. He received his BSc (Hons.) in Physiology and Biochemistry with Chemistry from the University of Reading, England, PhD in Protein Crystallography from Birkbeck College, University of London and medical degree from King’s College Hospital Medical School, University of London, England, United Kingdom. Dr. Mahadevan completed a post-doctoral Fogarty International Fellowship at the National Cancer Institute/NIH and was a senior research scientist at Celltech Therapeutics, London, England. He has written over 70 peer-reviewed full length articles included in Nature, Blood and the Journal of Clinical Oncology; several book chapters; and six U.S. patents on novel agents targeting cancer.

Dr. Mahadevan completed an internal medicine residency at University of Connecticut and fellowship training in Hematology/Oncology at the AZCC. Dr. Mahadevan is certified by the American Board of Internal Medicine and Medical Oncology.

“As Medical Scientist specializing in Phase I studies, I work very closely with Vector Oncology to provide informed opinion with regard to novel agents and help guide clinical trial opportunities for our patients.”

2014-08-20T12:57:47+00:00 August 20th, 2014|